Baxter Intl Inc SEC Filings

Baxter International Inc. reported first-quarter 2026 net sales of $2.70 billion, up 3% from $2.63 billion a year earlier, but swung to a net loss of $15 million, or $(0.03) per diluted share, versus net income of $126 million, or $0.25 per share.

Continuing operations posted a loss of $17 million, compared with $64 million of income in 2025, despite higher gross margin dollars. Results were heavily affected by $205 million of special items, including $146 million of intangible amortization and $68 million of restructuring and business optimization charges tied largely to the Kidney Care divestiture.

By segment, Medical Products & Therapies sales rose 2%, Healthcare Systems & Technologies were flat, and Pharmaceuticals grew 7%, driven by strong international drug compounding. However, Novum IQ pump shipment holds, injectables supply constraints, inflationary cost pressures and recall- and hurricane-related items weighed on profitability.

Operating cash flow improved sharply to $213 million from a $99 million use of cash a year ago, helped by working capital improvements. Baxter ended the quarter with $2.02 billion in cash and cash equivalents and $8.62 billion of long-term debt, while continuing multiyear cost-reduction and business transformation programs.

Baxter International reported first-quarter 2026 sales from continuing operations of $2.7 billion, up 3% on a reported basis but down 1% organically, reflecting flat to modestly weaker underlying demand. U.S. sales fell 4% while international sales grew 12% reported and 3% organically.

The company posted a U.S. GAAP net loss from continuing operations of $17 million, or ($0.03) per diluted share, compared with a profit a year ago. Adjusted diluted EPS from continuing operations was $0.36, down 35% from $0.55, as higher tariffs, manufacturing costs and prior-year comparison pressures weighed on results. Baxter’s board declared a quarterly dividend of $0.01 per share and the company reiterated its full-year 2026 outlook, targeting flat to 1% reported sales growth and adjusted diluted EPS of $1.85 to $2.05.

Baxter International Inc reports that Vanguard Capital Management beneficially owns 38,033,907 shares of Common Stock. The filing states this equals 7.36% of the class and that Vanguard has sole dispositive power over 38,033,907 shares and sole voting power over 4,526,932 shares. The filing is a Schedule 13G disclosure of passive ownership.

BAXTER INTERNATIONAL INC Schedule 13G/A shows BlackRock, Inc. reports beneficial ownership of 33,109,852 shares of common stock, representing 6.4% of the class as of the cover date. The filing lists sole voting power of 31,357,784 shares and sole dispositive power of 33,109,852 shares. The amendment is signed by a BlackRock managing director on 04/27/2026.

Baxter International: Pzena Investment Management reported beneficial ownership of 65,347,621 shares of Common Stock, representing 12.7% as of 03/31/2026. The filing states Pzena has sole voting power for 53,110,244 shares and sole dispositive power for 65,347,621 shares. It notes the shares are held for clients who retain the right to dividends and sale proceeds and that no single client accounts for more than 5% of the class.

Baxter International executive Julie Foster, President of Front Line Care, filed an initial ownership report showing both stock and option holdings. She directly holds 31,248 shares of common stock and a stock option covering 25,862 shares at an exercise price of $20.37 per share, expiring on February 27, 2036. The options become exercisable in three equal annual installments beginning on March 1, 2027, the first anniversary of the grant date.

Baxter International executive Steven P. Wallace, President of Advanced Surgery, reported his initial holdings on a Form 3. He directly owns 70,282 shares of common stock and holds several stock option awards covering additional shares at exercise prices between $20.37 and $74.47 with expirations from 2032 through 2036.

Baxter International Inc. executive James Teaff filed an initial Form 3 reporting his ownership of company securities. He reports direct ownership of 31,120 shares of Baxter common stock. The filing also lists several stock option awards, each giving the right to buy Baxter common shares at set exercise prices before future expiration dates.

These options cover blocks of shares at exercise prices ranging from $20.37 to $85.23 per share, with expiration dates between 2027 and 2036. Footnotes explain that the options generally become exercisable in three equal annual installments starting on the first anniversary of their respective grant dates. The filing records current holdings and does not reflect new open-market purchases or sales.

The Vanguard Group filed Amendment No. 11 to a Schedule 13G/A reporting that it beneficially owns 0 shares of Baxter International Inc. common stock, representing 0% of the class after an internal realignment. The filing states certain Vanguard subsidiaries will report ownership separately in accordance with SEC Release No. 34-39538, effective with the reorganization described, and that The Vanguard Group, Inc. no longer is deemed to beneficially own securities held by those subsidiaries. The amendment is signed by Ashley Grim as Head of Global Fund Administration on 03/26/2026.